Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies
- PMID: 20082954
- DOI: 10.1016/j.clindermatol.2009.03.001
Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies
Abstract
Instruments to measure and to monitor the severity of psoriasis over time are needed for research and for optimal patient care. Scoring psoriasis has moved from an earlier time when clinical categories were adopted without concern about their reliability; for example, from clearance to more recent semi-quantitative scores, such as the Psoriasis Area and Severity Index (PASI), that carry the allure of being objective and quantitative "hard" data but actually translate a subjective judgement into a number. The PASI score has never been standardized, and data on interrater and intrarater reliability are limited. Better clinimetrics of disease severity are needed. The next generation of instruments should reflect the major concern of patients and treating physicians relative to safe and effective long-term disease control for a lifelong condition.
Copyright 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment.J Am Acad Dermatol. 2004 Oct;51(4):563-9. doi: 10.1016/j.jaad.2004.04.012. J Am Acad Dermatol. 2004. PMID: 15389191 Clinical Trial.
-
A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index.Br J Dermatol. 2008 Aug;159(2):407-12. doi: 10.1111/j.1365-2133.2008.08680.x. Epub 2008 Jun 28. Br J Dermatol. 2008. PMID: 18565187
-
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.J Am Acad Dermatol. 2004 Jun;50(6):859-66. doi: 10.1016/j.jaad.2003.09.014. J Am Acad Dermatol. 2004. PMID: 15153885
-
The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab.Arch Dermatol Res. 2008 Nov;300(10):537-44. doi: 10.1007/s00403-008-0885-7. Epub 2008 Sep 11. Arch Dermatol Res. 2008. PMID: 18784934 Review.
-
Treatment goals in psoriasis.J Dtsch Dermatol Ges. 2007 Jul;5(7):566-74. doi: 10.1111/j.1610-0387.2007.06343.x. J Dtsch Dermatol Ges. 2007. PMID: 17610606 Review. English, German.
Cited by
-
Assessing the validity and interpretability of the Simplified Psoriasis Index in Tunisian patients.Tunis Med. 2022 Janvier;100(1):49-55. Tunis Med. 2022. PMID: 35822332 Free PMC article.
-
IL-17A, IL-22, IL-6, and IL-21 Serum Levels in Plaque-Type Psoriasis in Brazilian Patients.Mediators Inflamm. 2015;2015:819149. doi: 10.1155/2015/819149. Epub 2015 Aug 13. Mediators Inflamm. 2015. PMID: 26351408 Free PMC article.
-
Effect of Oral PUVAsol on the Quality of Life in Indian Patients Having Chronic Plaque Psoriasis.Dermatol Res Pract. 2014;2014:291586. doi: 10.1155/2014/291586. Epub 2014 Sep 4. Dermatol Res Pract. 2014. PMID: 25276121 Free PMC article.
-
Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity.Qual Life Res. 2013 Nov;22(9):2489-99. doi: 10.1007/s11136-013-0384-y. Epub 2013 Mar 9. Qual Life Res. 2013. PMID: 23475691 Clinical Trial.
-
Interleukin-21 is associated with the severity of psoriasis vulgaris through promoting CD4+ T cells to differentiate into Th17 cells.Am J Transl Res. 2016 Jul 15;8(7):3188-96. eCollection 2016. Am J Transl Res. 2016. PMID: 27508040 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical